Update on the Treatment of Behcet’s Disease of the Small Bowel with Biologic Agents

Yehyun Park, Jae Hee Cheon

Research output: Contribution to journalReview articlepeer-review

15 Citations (Scopus)


Purpose of Review: The treatment of intestinal Behcet’s disease (BD) is challenging, and one-third of patients require surgery due to failure of conventional therapies. Anti-tumor necrosis factor-α (TNF-α) and other new biologics have been actively investigated for managing intestinal BD. In this article, we review the updated experiences and up-to-date clinical data on anti-TNF-α and other biologics for the management of intestinal BD. Recent Findings: Recent prospective studies have proved the efficacy and safety of infliximab and adalimumab for treating intestinal BD. Recent studies with other biologics such as anti-interleukin (IL)-1 (anakinra and canakinumab) and anti-IL-6 (tocilizumab) have shown promising results in patients with systemic, including intestinal, BD. Summary: Both infliximab and adalimumab can be useful in managing patients with intestinal BD, especially severe or refractory cases, with a similar efficacy and safety profile. More evidence for anakinra, canakinumab, tocilizumab, anti-IL-17 (secukinumab), and anti-IL-12/23 (ustekinumab) in intestinal BD is required.

Original languageEnglish
Article number24
JournalCurrent gastroenterology reports
Issue number5
Publication statusPublished - 2020 May 1

Bibliographical note

Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.

All Science Journal Classification (ASJC) codes

  • Gastroenterology


Dive into the research topics of 'Update on the Treatment of Behcet’s Disease of the Small Bowel with Biologic Agents'. Together they form a unique fingerprint.

Cite this